Table 2.

Sociodemographic, Clinical, and Legal Characteristics of the Clozapine Group by Outcome of Competency Restoration

CharacteristicCompetent to Stand TrialPermanently Incompetent to Stand TrialP
Age, yearsa36.2 (7.3)28.9 (10.3).315
Time to opinion, daysa183.0 (83.0)225.0 (166.0)< .001
Length of stay, daysa214.0 (77.5)415.0 (324.0).063
Maximum clozapine dose prior to opiniona475.0 (275.0)400.0 (462.5).892
Clozapine dose at blood drawa375.0 (250.0)450.0 (300.0).314
Last clozapine level prior to opiniona397.0 (141.0)473.0 (431.0).209
Last norclozapine level prior to opiniona158.0 (43.0)293.0 (105.0).010
Clozapine dose upon dischargea425.0 (206.3)500.0 (250.0).593
Male7 (87.5)15 (88.2)1.000
Race1.000
    Non-Hispanic white4 (50.0)8 (47.1)
    Non-Hispanic black4 (50.0)9 (52.9)
Main psychiatric discharge diagnosis1.000
    Schizophrenia spectrum and other psychotic disorders7 (87.5)16 (94.1)
    Bipolar and related disorders1 (12.5)1 (5.9)
Charges type.339
    Felony7 (87.5)10 (62.5)
    Misdemeanor1 (12.5)2 (12.5)
    Both0 (0.0)4 (25.0)
Prior psychiatric treatment5 (62.5)17 (100.0).024
Antipsychotic use through stay
    Formulation1.000
        Oral5 (62.5)10 (58.8)
        Long-acting injectable ± oral3 (37.5)7 (41.2)
    Class.667
        Atypical4 (50.0)6 (35.3)
        Typical and atypical4 (50.0)11 (64.7)
    Number of antipsychotics through stay.320
        One1 (12.5)0 (0.0)
        Two or more7 (87.5)17 (100.0)
Psychiatric medications upon discharge
    Clozapine8 (100.0)7 (41.2).008
    Antipsychotics8 (100.0)16 (94.1)1.000
    Mood stabilizers3 (37.5)6 (35.3)1.000
    Antidepressants1 (12.5)4 (23.5)1.000

  • ↵a Data presented as median (interquartile range).

  • All other data are presented as n (%). Competent to Stand Trial Group: n = 8; Permanently Incompetent to Stand Trial Group: n = 17.